Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

This trial assessed adding an infusion of the drug nivolumab—or a placebo—to the pre-surgery phase and then assessing how patients respond overall, and the practice changing results have been ...

Bristol-Myers Squibb (NYSE:BMY) said that the Phase 3 RELATIVITY-098 study of its drug Opdualag in the treatment of late-stage melanoma didn't meet its primary endpoint. The drugmaker had been testing ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.

Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at ...

Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

Adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.